Translational mini-review series on immunology of vascular disease: Inflammation, infections and Toll-like receptors in cardiovascular disease

Clinical and Experimental Immunology

Volumn 156, Issue 3, 2009, Pages 386-394

  Ward, J R ^b   Wilson, H L ^b   Francis, S E ^b   Crossman, D C ^b   Sabroe, I ^a,b  

^a Academic Unit of Respiratory Medicine   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Atherosclerosis; Infection; Inflammation; Myocardial infarction; TLR

Indexed keywords

C REACTIVE PROTEIN; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; SCAVENGER RECEPTOR A; TOLL LIKE RECEPTOR;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CHLAMYDOPHILA PNEUMONIAE; CYTOMEGALOVIRUS; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HELICOBACTER PYLORI; HUMAN; INFECTION; INFLAMMATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; RISK FACTOR; STROKE; THROMBOGENESIS;

ATHEROSCLEROSIS; CYTOKINES; HUMANS; INFECTION; INFLAMMATION MEDIATORS; LIPIDS; MYOCARDIAL INFARCTION; STROKE; TOLL-LIKE RECEPTORS;

EID: 66149157864     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.03886.x     Document Type: Review

References (106)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006 367 : 1747 57. (Pubitemid 43767064)
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006 3 : e442.
3. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999 340 : 115 26. (Pubitemid 29054847)
4. Rangaswamy S, Penn MS, Saidel GM, Chisolm GM. Exogenous oxidized low-density lipoprotein injures and alters the barrier function of endothelium in rats in vivo. Circ Res 1997 80 : 37 44. (Pubitemid 27030366)
5. Tsao PS, Lewis NP, Alpert S, Cooke JP. Exposure to shear stress alters endothelial adhesiveness. Role of nitric oxide. Circulation 1995 92 : 3513 9.
6. Morris GE, Parker LC, Ward JR et al. Cooperative molecular and cellular networks regulate Toll-like receptor-dependent inflammatory responses. FASEB J 2006 20 : 2153 5.
7. Cohen Tervaert JW, 23 Cohen Tervaert JW. Translational Mini-Review Series on Immunology of Vascular Disease: Accelerated atherosclerosis in vasculitis. Clin Exp Immunol doi: 10.1111/j.1365-2249.2009.03885.x.
8. Maugeri N, Rovere-Querini P, Baldini M, Sabbadini MG, Manfredi AA. Translational Mini-Review Series on Immunology of Vascular Disease: Mechanisms of vascular inflammation and remodelling in systemic vasculitis. Clin Exp Immunol doi: 10.1111/j.1365-2249.2009.03921.x).
9. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987 316 : 1371 5. (Pubitemid 18014393)
10. Libby P. Inflammation in atherosclerosis. Nature 2002 420 : 868 74. (Pubitemid 36019640)
11. Chamberlain J, Evans D, King A et al. Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice. Am J Pathol 2006 168 : 1396 403.
12. Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem 2001 47 : 28 30. (Pubitemid 32064271)
13. Armani A, Becker RC. The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part II. Am Heart J 2005 149 : 977 83. (Pubitemid 40848140)
14. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008 359 : 2195 207.
15. Nievelstein PF, Fogelman AM, Mottino G, Frank JS. Lipid accumulation in rabbit aortic intima 2 hours after bolus infusion of low density lipoprotein. A deep-etch and immunolocalization study of ultrarapidly frozen tissue. Arterioscler Thromb 1991 11 : 1795 805.
16. Palinski W, Rosenfeld ME, Yla-Herttuala S et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989 86 : 1372 6. (Pubitemid 19061548)
17. Murphy JE, Tedbury PR, Homer-Vanniasinkam S, Walker JH, Ponnambalam S. Biochemistry and cell biology of mammalian scavenger receptors. Atherosclerosis 2005 182 : 1 15. (Pubitemid 41188365)
18. Nimrichter L, Burdick MM, Aoki K et al. E-selectin receptors on human leukocytes. Blood 2008 112 : 3744 52.
19. Jonjic N, Jilek P, Bernasconi S et al. Molecules involved in the adhesion and cytotoxicity of activated monocytes on endothelial cells. J Immunol 1992 148 : 2080 3.
20. Rose DM, Grabovsky V, Alon R, Ginsberg MH. The affinity of integrin alpha(4)beta(1) governs lymphocyte migration. J Immunol 2001 167 : 2824 30.
21. Huh HY, Pearce SF, Yesner LM, Schindler JL, Silverstein RL. Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation. Blood 1996 87 : 2020 8. (Pubitemid 26068918)
22. Jaakkola O, Nikkari T. Lipoprotein degradation and cholesterol esterification in primary cell cultures of rabbit atherosclerotic lesions. Am J Pathol 1990 137 : 457 65. (Pubitemid 20233006)
23. Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R. Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest 1994 93 : 1266 74. (Pubitemid 24087183)
24. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 1991 88 : 3739 43. (Pubitemid 21916699)
25. Gu L, Okada Y, Clinton SK et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998 2 : 275 81. (Pubitemid 128373654)
26. Veillard NR, Kwak B, Pelli G et al. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 2004 94 : 253 61. (Pubitemid 38197459)
27. Gerszten RE, Garcia-Zepeda EA, Lim YC et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999 398 : 718 23. (Pubitemid 29197651)
28. Mach F, Sauty A, Iarossi AS et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest 1999 104 : 1041 50. (Pubitemid 29536314)
29. Janabi M, Yamashita S, Hirano K et al. Oxidized LDL-induced NF-kappa B activation and subsequent expression of proinflammatory genes are defective in monocyte-derived macrophages from CD36-deficient patients. Arterioscler Thromb Vasc Biol 2000 20 : 1953 60. (Pubitemid 30648813)
30. Moshage H. Cytokines and the hepatic acute phase response. J Pathol 1997 181 : 257 66. (Pubitemid 27156836)
31. Mach F, Schonbeck U, Libby P. CD40 signaling in vascular cells: a key role in atherosclerosis Atherosclerosis 1998 137 (Suppl. S89 95. (Pubitemid 28294213)
32. Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 1993 178 : 669 74. (Pubitemid 23218216)
33. Cipollone F, Cicolini G, Bucci M. Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol Ther 2008 118 : 161 80.
34. O'Meara SJ, Rodgers K, Godson C. Lipoxins: update and impact of endogenous pro-resolution lipid mediators. Rev Physiol Biochem Pharmacol 2008 160 : 47 70.
35. Wittwer J, Hersberger M. The two faces of the 15-lipoxygenase in atherosclerosis. Prostaglandins Leukot Essent Fatty Acids 2007 77 : 67 77. (Pubitemid 47539103)
36. Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, Holt CM. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol 1996 16 : 1000 6. (Pubitemid 26266899)
37. Dewberry R, Holden H, Crossman D, Francis S. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol 2000 20 : 2394 400.
38. Steppich BA, Moog P, Matissek C et al. Cytokine profiles and T cell function in acute coronary syndromes. Atherosclerosis 2007 190 : 443 51. (Pubitemid 46074036)
39. Ferrari D, Pizzirani C, Adinolfi E et al. The P2X7 receptor: a key player in IL-1 processing and release. J Immunol 2006 176 : 3877 83. (Pubitemid 44264361)
40. Raines EW, Dower SK, Ross R. Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science 1989 243 : 393 6. (Pubitemid 19047517)
41. Kirii H, Niwa T, Yamada Y et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2003 23 : 656 60. (Pubitemid 36438080)
42. Isoda K, Shiigai M, Ishigami N et al. Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury. Circulation 2003 108 : 516 8. (Pubitemid 36961162)
43. Morton AC, Arnold ND, Gunn J et al. Interleukin-1 receptor antagonist alters the response to vessel wall injury in a porcine coronary artery model. Cardiovasc Res 2005 68 : 493 501. (Pubitemid 41566569)
44. Abbate A, Salloum FN, Vecile E et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 2008 117 : 2670 83.
45. Ikonomidis I, Lekakis JP, Nikolaou M et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 2008 117 : 2662 9.
46. Crossman DC, Morton AC, Gunn JP et al. Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study). Trials 2008 9 : 8.
47. Geng YJ, Wu Q, Muszynski M, Hansson GK, Libby P. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta. Arterioscler Thromb Vasc Biol 1996 16 : 19 27. (Pubitemid 26026927)
48. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994 94 : 2493 503. (Pubitemid 24379627)
49. Sukhova GK, Schonbeck U, Rabkin E et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999 99 : 2503 9. (Pubitemid 29228279)
50. Hatakeyama K, Asada Y, Marutsuka K, Sato Y, Kamikubo Y, Sumiyoshi A. Localization and activity of tissue factor in human aortic atherosclerotic lesions. Atherosclerosis 1997 133 : 213 9. (Pubitemid 27373498)
51. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006 47 : C13 18.
52. Greeno EW, Bach RR, Moldow CF. Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Lab Invest 1996 75 : 281 9. (Pubitemid 26272366)
53. Spencer FA, Goldberg RJ, Becker RC, Gore JM. Seasonal distribution of acute myocardial infarction in the second National Registry of Myocardial Infarction. J Am Coll Cardiol 1998 31 : 1226 33. (Pubitemid 28219110)
54. Spielberg C, Falkenhahn D, Willich SN, Wegscheider K, Voller H. Circadian, day-of-week, and seasonal variability in myocardial infarction: comparison between working and retired patients. Am Heart J 1996 132 : 579 85. (Pubitemid 26347762)
55. Madjid M, Naghavi M, Litovsky S, Casscells SW. Influenza and cardiovascular disease: a new opportunity for prevention and the need for further studies. Circulation 2003 108 : 2730 6. (Pubitemid 37498972)
56. Naghavi M, Barlas Z, Siadaty S, Naguib S, Madjid M, Casscells W. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 2000 102 : 3039 45.
57. Siscovick DS, Raghunathan TE, Lin D et al. Influenza vaccination and the risk of primary cardiac arrest. Am J Epidemiol 2000 152 : 674 7.
58. Lavallee P, Perchaud V, Gautier-Bertrand M, Grabli D, Amarenco P. Association between influenza vaccination and reduced risk of brain infarction. Stroke 2002 33 : 513 18. (Pubitemid 34123398)
59. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003 348 : 1322 32. (Pubitemid 36384099)
60. Meier CR, Jick SS, Derby LE, Vasilakis C, Jick H. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet 1998 351 : 1467 71. (Pubitemid 28227037)
61. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004 351 : 2611 18. (Pubitemid 39628582)
62. Clayton TC, Thompson M, Meade TW. Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur Heart J 2008 29 : 96 103.
63. Madjid M, Miller CC, Zarubaev VV et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34 892 subjects. Eur Heart J 2007 28 : 1205 10. (Pubitemid 47343835)
64. Naghavi M, Wyde P, Litovsky S et al. Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-deficient mice. Circulation 2003 107 : 762 8. (Pubitemid 36222607)
65. Madjid M, Vela D, Khalili-Tabrizi H, Casscells SW, Litovsky S. Systemic infections cause exaggerated local inflammation in atherosclerotic coronary arteries: clues to the triggering effect of acute infections on acute coronary syndromes. Tex Heart Inst J 2007 34 : 11 18. (Pubitemid 46588479)
66. Keller TT, van der Meer JJ, Teeling P et al. Selective expansion of influenza A virus-specific T cells in symptomatic human carotid artery atherosclerotic plaques. Stroke 2008 39 : 174 9.
67. Campbell LA, Kuo CC. Chlamydia pneumoniae - infectious risk factor for atherosclerosis Nat Rev Microbiol 2004 2 : 23 32. (Pubitemid 39490045)
68. Gibson FC III., Yumoto H, Takahashi Y, Chou HH, Genco CA. Innate immune signaling and Porphyromonas gingivalis-accelerated atherosclerosis. J Dent Res 2006 85 : 106 21.
69. Gibson FC III., Genco CA. Porphyromonas gingivalis mediated periodontal disease and atherosclerosis: disparate diseases with commonalities in pathogenesis through TLRs. Curr Pharm Des 2007 13 : 3665 75.
70. Gasbarrini A, Cremonini F, Armuzzi A et al. The role of Helicobacter pylori in cardiovascular and cerebrovascular diseases. J Physiol Pharmacol 1999 50 : 735 42. (Pubitemid 30090008)
71. Adam E, Melnick JL, DeBakey ME. Cytomegalovirus infection and atherosclerosis. Cent Eur J Public Health 1997 5 : 99 106. (Pubitemid 127467269)
72. Sabroe I, Read RC, Whyte MK, Dockrell DH, Vogel SN, Dower SK. Toll-like receptors in health and disease: complex questions remain. J Immunol 2003 171 : 1630 5. (Pubitemid 36966443)
73. Poltorak A, He X, Smirnova I et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998 282 : 2085 8. (Pubitemid 29001265)
74. Sasu S, LaVerda D, Qureshi N, Golenbock DT, Beasley D. Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ Res 2001 89 : 244 50. (Pubitemid 34132682)
75. Kurt-Jones EA, Popova L, Kwinn L et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000 1 : 398 401.
76. Taylor KR, Trowbridge JM, Rudisill JA, Termeer CC, Simon JC, Gallo RL. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J Biol Chem 2004 279 : 17079 84. (Pubitemid 38560463)
77. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001 167 : 2887 94. (Pubitemid 32768923)
78. Malley R, Henneke P, Morse SC et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA 2003 100 : 1966 71. (Pubitemid 36254557)
79. Takeuchi O, Kawai T, Muhlradt PF et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 2001 13 : 933 40. (Pubitemid 32685205)
80. Takeuchi O, Sato S, Horiuchi T et al. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002 169 : 10 14. (Pubitemid 34686113)
81. Cheng N, He R, Tian J, Ye PP, Ye RD. Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J Immunol 2008 181 : 22 6.
82. Hayashi F, Smith KD, Ozinsky A et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001 410 : 1099 103. (Pubitemid 32391041)
83. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001 413 : 732 8. (Pubitemid 33009951)
84. Kariko K, Ni H, Capodici J, Lamphier M, Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 2004 279 : 12542 50. (Pubitemid 38445825)
85. Diebold SS, Kaisho T, Hemmi H, Akira S, Reise Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004 303 : 1529 31. (Pubitemid 38314425)
86. Heil F, Hemmi H, Hochrein H et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004 303 : 1526 9. (Pubitemid 38314424)
87. Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002 3 : 196 200. (Pubitemid 34141451)
88. Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000 408 : 740 5. (Pubitemid 32015992)
89. Brand K, Page S, Rogler G et al. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996 97 : 1715 22. (Pubitemid 26105480)
90. Visintin A, Mazzoni A, Spitzer JH, Wyllie DH, Dower SK, Segal DM. Regulation of Toll-like receptors in human monocytes and dendritic cells. J Immunol 2001 166 : 249 55. (Pubitemid 32038439)
91. Faure E, Equils O, Sieling PA et al. Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem 2000 275 : 11058 63. (Pubitemid 30212746)
92. Ward JR, Bingle L, Judge HM et al. Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor. Thromb Haemost 2005 94 : 831 8. (Pubitemid 41489246)
93. Tan X, Essengue S, Talreja J, Reese J, Stechschulte DJ, Dileepan KN. Histamine directly and synergistically with lipopolysaccharide stimulates cyclooxygenase-2 expression and prostaglandin I(2) and E(2) production in human coronary artery endothelial cells. J Immunol 2007 179 : 7899 906.
94. Talreja J, Kabir MH, Filla MB, Stechschulte DJ, Dileepan KN. Histamine induces Toll-like receptor 2 and 4 expression in endothelial cells and enhances sensitivity to Gram-positive and Gram-negative bacterial cell wall components. Immunology 2004 113 : 224 33. (Pubitemid 39312450)
95. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002 105 : 1158 61. (Pubitemid 34225814)
96. Schoneveld AH, Hoefer I, Sluijter JP, Laman JD, de Kleijn DP, Pasterkamp G. Atherosclerotic lesion development and Toll like receptor 2 and 4 responsiveness. Atherosclerosis 2008 197 : 95 104.
97. Xu XH, Shah PK, Faure E et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001 104 : 3103 8. (Pubitemid 34014065)
98. Castrillo A, Joseph SB, Vaidya SA et al. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell 2003 12 : 805 16. (Pubitemid 37352775)
99. Michelsen KS, Wong MH, Shah PK et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004 101 : 10679 84. (Pubitemid 38955802)
100. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest 2005 115 : 3149 56. (Pubitemid 41567579)
101. Naiki Y, Sorrentino R, Wong MH et al. TLR/MyD88 and liver X receptor alpha signaling pathways reciprocally control Chlamydia pneumoniae-induced acceleration of atherosclerosis. J Immunol 2008 181 : 7176 85.
102. Wiedermann CJ, Kiechl S, Dunzendorfer S et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol 1999 34 : 1975 81. (Pubitemid 30002653)
103. Lehr HA, Sagban TA, Ihling C et al. Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation 2001 104 : 914 20. (Pubitemid 32778043)
104. Engelmann MG, Redl CV, Nikol S. Recurrent perivascular inflammation induced by lipopolysaccharide (endotoxin) results in the formation of atheromatous lesions in vivo. Lab Invest 2004 84 : 425 32. (Pubitemid 41656470)
105. Vink A, Schoneveld AH, van der Meer JJ et al. In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation 2002 106 : 1985 90. (Pubitemid 35176306)
106. Schoneveld AH, Oude Nijhuis MM, van Middelaar B, Laman JD, de Kleijn DP, Pasterkamp G. Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development. Cardiovasc Res 2005 66 : 162 9. (Pubitemid 40357879)